title: CA 19-9 in pancreatic cancer.
abstract: CA 19-9 has achieved a defined role in the diagnosis, prognosis, and monitoring of patients with pancreatic cancer. For diagnosis, a reference value above 200 u/mL in a nonjaundiced patient with a confirming CT scan has a very high predictive value. For prognosis, a low preoperative value and a normal value after resection predict a good outcome. Similarly, CA 19-9 levels have been used successfully in monitoring the response to neoadjuvant therapy.
authors.affiliation: Mayo Medical School, Mayo Clinic Foundation, Rochester, Minnesota, USA.
authors.forename: R E
authors.initials: RE
authors.lastname: Ritts
authors.forename: H A
authors.initials: HA
authors.lastname: Pitt
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D018395:CA-19-9 Antigen / Q000032:analysis*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000628:therapy; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen